MA44732B1 - Procédés de production d'arn simple brin - Google Patents
Procédés de production d'arn simple brinInfo
- Publication number
- MA44732B1 MA44732B1 MA44732A MA44732A MA44732B1 MA 44732 B1 MA44732 B1 MA 44732B1 MA 44732 A MA44732 A MA 44732A MA 44732 A MA44732 A MA 44732A MA 44732 B1 MA44732 B1 MA 44732B1
- Authority
- MA
- Morocco
- Prior art keywords
- stranded rna
- production processes
- rna production
- arnsb
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des procédés qui permettent d'obtenir de l'arn simple brin (arnsb). En outre, la présente invention concerne l'arnsb qui peut être obtenu selon les procédés de l'invention et l'utilisation dudit arnsb en thérapie.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2016059056 | 2016-04-22 | ||
| PCT/EP2017/059293 WO2017182524A1 (fr) | 2016-04-22 | 2017-04-19 | Procédés de production d'arn simple brin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44732A MA44732A (fr) | 2021-06-02 |
| MA44732B1 true MA44732B1 (fr) | 2021-11-30 |
Family
ID=58699087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44732A MA44732B1 (fr) | 2016-04-22 | 2017-04-19 | Procédés de production d'arn simple brin |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20190153425A1 (fr) |
| EP (2) | EP3445850B1 (fr) |
| JP (2) | JP7000343B2 (fr) |
| KR (2) | KR102565881B1 (fr) |
| CN (1) | CN109072232B (fr) |
| AU (1) | AU2017251983B2 (fr) |
| BR (1) | BR112018069417A2 (fr) |
| CA (1) | CA3020481A1 (fr) |
| CY (1) | CY1124845T1 (fr) |
| DK (1) | DK3445850T3 (fr) |
| ES (1) | ES2900272T3 (fr) |
| HR (1) | HRP20211745T1 (fr) |
| HU (1) | HUE059314T2 (fr) |
| IL (1) | IL262304A (fr) |
| LT (1) | LT3445850T (fr) |
| MA (1) | MA44732B1 (fr) |
| MD (1) | MD3445850T2 (fr) |
| MX (1) | MX2018012880A (fr) |
| PL (1) | PL3445850T3 (fr) |
| PT (1) | PT3445850T (fr) |
| RS (1) | RS62612B1 (fr) |
| RU (2) | RU2760790C2 (fr) |
| SG (2) | SG10202010471UA (fr) |
| SI (1) | SI3445850T1 (fr) |
| WO (1) | WO2017182524A1 (fr) |
| ZA (2) | ZA201805949B (fr) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012880A (es) | 2016-04-22 | 2019-03-28 | Biontech Rna Pharmaceuticals Gmbh | Metodos para proporcionar arn de hebra sencilla. |
| WO2018188730A1 (fr) | 2017-04-11 | 2018-10-18 | Biontech Rna Pharmaceuticals Gmbh | Arn pour le traitement de maladies auto-immunes |
| MA49922A (fr) | 2017-08-18 | 2021-06-02 | Modernatx Inc | Procédés pour analyse par clhp |
| AU2020329166A1 (en) | 2019-08-09 | 2022-03-03 | Nutcracker Therapeutics, Inc. | Microfluidic apparatus and methods of use thereof |
| WO2021160346A1 (fr) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Vaccin à base d'acide nucléique contre le coronavirus sars-cov-2 |
| KR20220161316A (ko) | 2020-03-30 | 2022-12-06 | 비온테크 에스이 | Claudin-18.2를 표적화하는 rna 조성물 |
| EP3896161A1 (fr) * | 2020-04-17 | 2021-10-20 | Bia Separations D.O.O. | Procédé de purification d'arn simple brin |
| EP3896159A1 (fr) * | 2020-04-17 | 2021-10-20 | Bia Separations D.O.O. | Procédé de purification d'arn simple brin utilisant un échangeur d'anions |
| EP3896160A1 (fr) * | 2020-04-17 | 2021-10-20 | Bia Separations D.O.O. | Procédé de purification d'arn simple brin |
| US20230174966A1 (en) | 2020-06-19 | 2023-06-08 | Etherna Immunotherapies Nv | Rna purification method |
| WO2022218503A1 (fr) | 2021-04-12 | 2022-10-20 | BioNTech SE | Compositions de npl comprenant de l'arn et procédés de préparation, de stockage et d'utilisation de celles-ci |
| WO2022101486A1 (fr) | 2020-11-16 | 2022-05-19 | BioNTech SE | Compositions pharmaceutiques comprenant des particules et de l'arnm et leurs procédés de préparation et de stockage |
| AU2021379090A1 (en) | 2020-11-16 | 2023-06-15 | BioNTech SE | Lnp compositions comprising rna and methods for preparing, storing and using the same |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| CN115197935A (zh) * | 2021-04-08 | 2022-10-18 | 上海细胞治疗集团有限公司 | 纤维素色谱纯化rna的方法 |
| WO2022218891A2 (fr) | 2021-04-12 | 2022-10-20 | BioNTech SE | Compositions d'arn comprenant une substance tampon et procédés de préparation, de stockage et d'utilisation de celles-ci |
| JP2024518335A (ja) | 2021-04-26 | 2024-05-01 | アンスティチュ パスツール | ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 |
| WO2022266038A1 (fr) * | 2021-06-14 | 2022-12-22 | 2Seventy Bio, Inc. | Procédés de purification d'arn simple brin |
| US20240218353A1 (en) * | 2021-06-17 | 2024-07-04 | Modernatx, Inc. | Alternative rna purification strategies |
| CN115505589A (zh) * | 2021-07-27 | 2022-12-23 | 上海兆维科技发展有限公司 | 一种rna的制备方法、合成蛋白质的方法以及转录反应液 |
| TW202320842A (zh) | 2021-07-29 | 2023-06-01 | 德商拜恩技術股份公司 | 用於治療黑色素瘤之組合物及方法 |
| WO2023030635A1 (fr) | 2021-09-02 | 2023-03-09 | BioNTech SE | Test d'activité pour potentiel thérapeutique d'acide nucléique codant |
| JP2024535766A (ja) | 2021-09-10 | 2024-10-02 | バイオエヌテック エスエー | 治療に適した脂質ベースのｒｎａ製剤 |
| WO2023051926A1 (fr) | 2021-09-30 | 2023-04-06 | BioNTech SE | Traitement impliquant un arn non immunogène pour vaccination antigénique et antagonistes liant l'axe pd-1 |
| WO2023067193A2 (fr) | 2021-10-22 | 2023-04-27 | BioNTech SE | Compositions pour l'administration de différentes doses d'arn |
| EP4422698A1 (fr) | 2021-10-29 | 2024-09-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
| KR20240099240A (ko) * | 2021-11-08 | 2024-06-28 | 그릿스톤 바이오, 인코포레이티드 | 자가 증폭 rna 조성물 및 이의 사용 방법 |
| WO2023083434A1 (fr) | 2021-11-09 | 2023-05-19 | BioNTech SE | Arn codant pour la peptidoglycane hydrolase et son utilisation pour le traitement d'une infection bactérienne |
| WO2023126053A1 (fr) | 2021-12-28 | 2023-07-06 | BioNTech SE | Formulations à base de lipides pour administration d'arn |
| AU2023212857A1 (en) | 2022-01-27 | 2024-07-04 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| AU2023225791A1 (en) * | 2022-02-28 | 2024-09-05 | Revvity Health Sciences, Inc. | Methods for separating and detecting double-stranded and single-stranded ribonucleic acid (rna) |
| WO2023165681A1 (fr) | 2022-03-01 | 2023-09-07 | BioNTech SE | Nanoparticules lipidiques (npl) d'arn comprenant un polymère de polyoxazoline et/ou de polyoxazine |
| KR20230142248A (ko) | 2022-04-01 | 2023-10-11 | 주식회사 엘지에너지솔루션 | 연성회로기판을 포함하는 파우치형 전지셀 |
| WO2023193892A1 (fr) | 2022-04-05 | 2023-10-12 | BioNTech SE | Compositions d'acide nucléique comprenant un polyphosphate inorganique et procédés de préparation, de stockage et d'utilisation de celles-ci |
| WO2023218431A1 (fr) | 2022-05-13 | 2023-11-16 | BioNTech SE | Compositions d'arn ciblant le vih |
| CN114921457B (zh) * | 2022-05-16 | 2023-09-29 | 硅羿科技（上海）有限公司 | 一种提取dsRNA的方法 |
| WO2023230295A1 (fr) | 2022-05-25 | 2023-11-30 | BioNTech SE | Compositions d'arn pour l'administration d'antigènes de la variole du singe et méthodes associées |
| WO2024017479A1 (fr) | 2022-07-21 | 2024-01-25 | BioNTech SE | Cellules multifonctionnelles exprimant de manière transitoire un récepteur immunitaire et une ou plusieurs cytokines, leur utilisation et leurs procédés de production |
| WO2024028325A1 (fr) | 2022-08-01 | 2024-02-08 | BioNTech SE | Compositions d'acide nucléique contenant des composés conjugués-oligo éthylène glycol (oeg) amphiphiles et procédés d'utilisation de tels composés et compositions |
| WO2024028445A1 (fr) | 2022-08-03 | 2024-02-08 | BioNTech SE | Arn pour la prévention ou le traitement de la tuberculose |
| WO2024027910A1 (fr) | 2022-08-03 | 2024-02-08 | BioNTech SE | Arn pour la prévention ou le traitement de la tuberculose |
| WO2024063789A1 (fr) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions pour l'administration d'antigènes du paludisme et méthodes associées |
| WO2024063788A1 (fr) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions pour l'administration d'antigènes du paludisme et méthodes associées |
| WO2024064931A1 (fr) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions pour l'administration d'antigènes du stade hépatique et méthodes associées |
| WO2024064934A1 (fr) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions pour administration d'antigènes csp de plasmodium et procédés associés |
| WO2024074211A1 (fr) | 2022-10-06 | 2024-04-11 | BioNTech SE | Compositions d'arn ciblant la claudine-18.2 |
| WO2024074634A1 (fr) | 2022-10-06 | 2024-04-11 | BioNTech SE | Compositions d'arn ciblant la claudine 18.2 |
| WO2024141955A1 (fr) | 2022-12-28 | 2024-07-04 | BioNTech SE | Compositions d'arn ciblant le vih |
| WO2024153324A1 (fr) | 2023-01-18 | 2024-07-25 | BioNTech SE | Formulations d'arn à usage pharmaceutique |
| WO2024180363A1 (fr) | 2023-02-28 | 2024-09-06 | BioNTech SE | Dosages de puissance de séquence de lieur pour de multiples acides nucléiques codants |
| WO2024180054A1 (fr) | 2023-02-28 | 2024-09-06 | BioNTech SE | Dosages de puissance de séquence de lieur pour de multiples acides nucléiques codants |
| WO2024184533A1 (fr) | 2023-03-09 | 2024-09-12 | BioNTech SE | Peptidoglycane hydrolases à activité bactéricide |
| EP4442276A1 (fr) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Anticorps combinés contre les sarcovirus et leurs utilisations |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2936240A1 (de) * | 1979-09-07 | 1981-03-26 | Bayer Ag, 51373 Leverkusen | Verfahren zur herstellung bekannter und neuer 6-amino-6-desoxy-2,3-0-isopropyliden-(alpha)-l-sorbofuranose-derivate sowie neue zwischenprodukte des verfahrens |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| NL8900725A (nl) * | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | Werkwijze en combinatie van middelen voor het isoleren van nucleinezuur. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| JP3692395B2 (ja) * | 2000-09-01 | 2005-09-07 | 独立行政法人農業・生物系特定産業技術研究機構 | ベクターモノカリオンを用いた紫紋羽病菌に対するゲノムが２本鎖ｒｎａである糸状菌に寄生するウイルスを導入する新規方法 |
| EP2216415B2 (fr) * | 2003-08-01 | 2017-01-04 | Life Technologies Corporation | Compositions et procédés de préparation de courtes molécules d'ARN et d'autres acides nucléiques |
| US9012219B2 (en) * | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2009528845A (ja) * | 2006-03-08 | 2009-08-13 | プロメガ・コーポレーション | 低分子量ｒｎａの精製方法 |
| CN101086011B (zh) * | 2006-06-08 | 2010-12-08 | 河南农业大学 | 食用菌和植物双链rna病毒检测试剂盒及其应用 |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| WO2008157688A2 (fr) | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthèse et utilisation d'analogues de phosphorothioate anti-inverse de la coiffe d'arn messager |
| SI3112467T1 (en) | 2009-12-07 | 2018-06-29 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| CA2862377A1 (fr) * | 2011-12-30 | 2013-07-04 | Cellscript, Llc | Fabrication et utilisation d'arnss synthetises in vitro pour introduction dans des cellules mammaliennes afin d'induire un effet biologique ou biochimique |
| EP4108769B1 (fr) * | 2015-05-29 | 2023-08-30 | CureVac Manufacturing GmbH | Procédé de production et de purification de l'arn, comprenant au moins une étape de filtration à flux tangentiel |
| MX2018012880A (es) | 2016-04-22 | 2019-03-28 | Biontech Rna Pharmaceuticals Gmbh | Metodos para proporcionar arn de hebra sencilla. |
-
2017
- 2017-04-19 MX MX2018012880A patent/MX2018012880A/es unknown
- 2017-04-19 SG SG10202010471UA patent/SG10202010471UA/en unknown
- 2017-04-19 WO PCT/EP2017/059293 patent/WO2017182524A1/fr active Application Filing
- 2017-04-19 PT PT177226958T patent/PT3445850T/pt unknown
- 2017-04-19 DK DK17722695.8T patent/DK3445850T3/da active
- 2017-04-19 PL PL17722695T patent/PL3445850T3/pl unknown
- 2017-04-19 CN CN201780024328.9A patent/CN109072232B/zh active Active
- 2017-04-19 RU RU2018136601A patent/RU2760790C2/ru active
- 2017-04-19 US US16/091,389 patent/US20190153425A1/en active Pending
- 2017-04-19 HU HUE17722695A patent/HUE059314T2/hu unknown
- 2017-04-19 EP EP17722695.8A patent/EP3445850B1/fr active Active
- 2017-04-19 HR HRP20211745TT patent/HRP20211745T1/hr unknown
- 2017-04-19 CA CA3020481A patent/CA3020481A1/fr active Pending
- 2017-04-19 KR KR1020227009308A patent/KR102565881B1/ko active IP Right Grant
- 2017-04-19 RS RS20211459A patent/RS62612B1/sr unknown
- 2017-04-19 EP EP21204500.9A patent/EP4008782A1/fr active Pending
- 2017-04-19 JP JP2018555164A patent/JP7000343B2/ja active Active
- 2017-04-19 KR KR1020187030368A patent/KR102378404B1/ko active IP Right Grant
- 2017-04-19 BR BR112018069417A patent/BR112018069417A2/pt not_active IP Right Cessation
- 2017-04-19 RU RU2021134269A patent/RU2021134269A/ru unknown
- 2017-04-19 MD MDE20190258T patent/MD3445850T2/ro unknown
- 2017-04-19 MA MA44732A patent/MA44732B1/fr unknown
- 2017-04-19 LT LTEPPCT/EP2017/059293T patent/LT3445850T/lt unknown
- 2017-04-19 AU AU2017251983A patent/AU2017251983B2/en active Active
- 2017-04-19 ES ES17722695T patent/ES2900272T3/es active Active
- 2017-04-19 SG SG11201807573VA patent/SG11201807573VA/en unknown
- 2017-04-19 SI SI201730980T patent/SI3445850T1/sl unknown
-
2018
- 2018-09-05 ZA ZA2018/05949A patent/ZA201805949B/en unknown
- 2018-10-11 IL IL262304A patent/IL262304A/en unknown
-
2019
- 2019-08-22 ZA ZA2019/05536A patent/ZA201905536B/en unknown
-
2021
- 2021-11-26 CY CY20211101032T patent/CY1124845T1/el unknown
- 2021-12-23 JP JP2021209047A patent/JP7335313B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44732B1 (fr) | Procédés de production d'arn simple brin | |
| MX2023010757A (es) | Variantes de proteasa y sus usos. | |
| PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
| WO2017064566A3 (fr) | Modification inductible d'un génome cellulaire | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| EP4234693A3 (fr) | Protéases à sérines du clade du bacillus gibsonii | |
| EP4335874A3 (fr) | Anticorps anti-hla-g et leur utilisation | |
| CA163246S (en) | Handle for toothbrush | |
| WO2016094837A3 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| GEP20217252B (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| WO2015200902A8 (fr) | Endophytes, compositions associées et leurs méthodes d'utilisation | |
| NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| MA40132A1 (fr) | Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li | |
| WO2015002724A3 (fr) | Cellules β dérivées de cellules souches et compositions et procédés pour générer ces cellules | |
| CR20140529A (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
| WO2015011694A3 (fr) | Isotopologues d'oligonucléotides antisens smad7 | |
| WO2016065349A8 (fr) | Arn non codants courts régulateurs de protéines (sprrna) et procédés d'utilisation | |
| MX2017009937A (es) | Cepas fungicas y metodos de uso. | |
| WO2016001754A3 (fr) | Procédés de reconstruction tridimensionnelle et de détermination de la qualité d'un embryon | |
| WO2017087912A3 (fr) | Biocapteurs ratiométriques et transfert d'énergie par résonance de förster non modulé géométriquement | |
| WO2015077657A3 (fr) | Inhibiteurs de stat3 et leurs utilisations | |
| WO2017048809A8 (fr) | Cellules nk présentant un phénotype adaptatif, et procédés de préparation et d'utilisation | |
| WO2015058132A3 (fr) | Anticorps anti-rspo et leurs méthodes d'utilisation | |
| WO2017066622A3 (fr) | Méthodes d'évaluation génomique du bétail | |
| MX2019000057A (es) | Acero de alto límite de elasticidad. |